Drug Approval | October 23, 2023
Natco Pharma receives 8 observations from USFDA for Pharma Division at Kothur
The company is confident of addressing all the observations within the stipulated time
The company is confident of addressing all the observations within the stipulated time
This exposé embarks on an illuminative journey, unfurling the crucial stratagems imperative for upholding public health, achieved through the unyielding fortress of pharmaceutical quality safeguards
This is a strategic acquisition for Cipla South Africa to unlock the future growth opportunities in the South African market
Weinand is the former CEO and Chairman of the Board at Bayer Pharma AG, leading Bayer’s fully integrated $20 billion healthcare business
The deal represents a total transaction value of up to $36 million with an initial upfront consideration of $14 million
The Long-term Safety Trial was approved to be conducted by China National Medical Products Administration (NMPA) on 18 April 2023
Rare childhood cancer subtype, Ph+ ALL, is found in 3-4% of pediatric cases and 25% of adult cases
This trial is a multi-national, phase 2/3, open-label, randomized, controlled clinical study of utidelone injectable
Cooperative agreement with U.S. Government to advance U.S. biopharma industry and ensure pandemic preparedness
FDA’s NME approvals declined substantially in 2022, causing overall New Drug Application (NDA) approvals to drop
Subscribe To Our Newsletter & Stay Updated
